Home Featured Page 234

Featured

Latest

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Filament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin

PTSF63 – The Media and Legalization, Joints for Jabs, and 40,000...

Atai Targets $2.3bn Valuation in Nasdaq IPO

atai Life Sciences Announces Launch of Initial Public Offering

Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit...

Red Light Holland Closes Acquisition of 80% of Happy Caps Mushroom...

PharmaTher Provides Research and Development Update and Milestones for 2021

MYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder...

Filament Cultivates 20th Psychedelic Mushroom Variety and Provides Propagation Update

1...233234235...291 Page 234 of 291

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Filament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin

PTSF63 – The Media and Legalization, Joints for Jabs, and 40,000...

Atai Targets $2.3bn Valuation in Nasdaq IPO

atai Life Sciences Announces Launch of Initial Public Offering

LSD and the Anarchic Brain

Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit...

Red Light Holland Closes Acquisition of 80% of Happy Caps Mushroom...

PharmaTher Provides Research and Development Update and Milestones for 2021

MYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder...

Filament Cultivates 20th Psychedelic Mushroom Variety and Provides Propagation Update

EDITOR PICKS

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY